Top

Published in:

Open Access 02-01-2024 | Breast Cancer

PARP Inhibitors in Breast Cancer: a Short Communication

Authors: Gordon R. Daly, Maen Monketh AlRawashdeh, Jason McGrath, Gavin P. Dowling, Luke Cox, Sindhuja Naidoo, Damir Vareslija, Arnold D. K Hill, Leonie Young

Published in: Current Oncology Reports | Issue 2/2024

Abstract

Purpose of Review

In the last decade, poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in the treatment of several cancers, such as breast and ovarian cancer. This article aims to discuss the current uses, limitations, and future directions for PARP inhibitors (PARPis) in the treatment of breast cancer.

Recent Findings

Following the results of the OlympiAD and EMBRACA trials, PARPis were approved in HER2-negative breast cancer with a germline BRCA mutation. We reviewed this class of drugs’ mechanism of action, efficacy, and limitations, as well as further studies that discussed resistance, impaired homologous recombination repair (HRR), and the combination of PARPis with other drugs.

Summary

Improving understanding of HRR, increasing the ability to target resistance, and combining PARPis with other novel agents are continuing to increase the clinical utility of PARPis.

Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033.PubMedCrossRef

Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–50.PubMedCrossRef

Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.PubMedCrossRef

American Cancer Society. Cancer facts & figures 2022. Atlanta: American Cancer Society; 2022.

Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255–82.PubMedPubMedCentralCrossRef

Baretta Z, et al. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(40):e4975.PubMedPubMedCentralCrossRef

Llop-Guevara A, et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann Oncol. 2021;32(12):1590–6.PubMedCrossRef

Cruz C, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203–10.PubMedPubMedCentralCrossRef

Herzog TJ, et al. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: a current perspective. Eur J Cancer. 2023;179:136–46.PubMedCrossRef

10.

•• Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33. The OlympiAD trial lead to the licensing of olaparib in metastatic, HER2-negative breast cancer with germline BRCA mutation.PubMedCrossRef

11.

Lynparza: highlights of prescribing information (May 2023). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf (Accessed: 07 November 2023)

12.

European Medicines Agency. (2021). Lynparza. European Medicines Agency.https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf (Accessed: 07 November 2023).

13.

•• Litton JK, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–63. The EMBRACA trial lead to the licensing of talazoparib in metastatic, HER2-negative breast cancer with germline BRCA mutation.PubMedPubMedCentralCrossRef

14.

Talzenna: highlights of prescribing information (June 2023). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf (Accessed: 07 November 2023).

15.

Tung N, Garber JE. PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer. 2022;8(1):47.PubMedPubMedCentralCrossRef

16.

•• Tutt ANJ, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–405. The OlympiA trial lead to the licensing of olaparib for high-risk early HER2 - negative breast cancer with a germline BRCA mutation.PubMedPubMedCentralCrossRef

17.

• Rubraca FDA Rubraca: highlights of prescribing information. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf. Accessed 7 Nov 2023. Current FDA label of rucaparib.

18.

Toms C, Chopra N, Houlton L, Jarman K, Kilburn L, Bliss J, et al. Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO). Ann Oncol. 2016;27(Supplement 6):vi43–67. https://doi.org/10.1093/annonc/mdw364.75.

19.

• Zejula: highlights of prescribing information. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Current FDA label of niraparib.

20.

Vinayak S, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132–40.PubMedPubMedCentralCrossRef

21.

Li H, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107.PubMedPubMedCentralCrossRef

22.

D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018;71:172–6.PubMedCrossRef

23.

• LaFargue CJ, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15–28. Published in Lancet Oncology, this review compares the side effect/ adverse events of PARP inhibitors in ovarian cancer.PubMedPubMedCentralCrossRef

24.

Paluch-Shimon S. Managing side effects of PARP inhibitors. In ESMO 2018 Congress. Munich, Germany 2018.

25.

Li J, Zhang Z. Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. J Chemotherapy. 2021;33(7):452–61.CrossRef

26.

Friedlander M, et al. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021;22(5):632–42.PubMedCrossRef

27.

Sun W, et al. Gastrointestinal events with PARP inhibitors in cancer patients: a meta-analysis of phase II/III randomized controlled trials. J Clin Pharm Ther. 2021;46(2):241–55.PubMedCrossRef

28.

Eakin CM, et al. Management of nausea and vomiting from poly (ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer. Gynecol Oncol. 2020;159(2):581–7.PubMedCrossRef

29.

Colombo N, et al. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021;163(1):41–9.MathSciNetPubMedPubMedCentralCrossRef

30.

European Medicines Agency. (2021). Talzenna. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf (Accessed: 07 November 2023).

31.

Ma Z, et al. Risk of pneumonitis in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecol Oncol. 2021;162(2):496–505.PubMedCrossRef

32.

McLaren A, et al. First-line PARP inhibitors-emerging side effects require caution: a case of PARPi-induced pneumonitis. J Immunother Precis Oncol. 2021;4(3):171–4.PubMedPubMedCentralCrossRef

33.

Friedlander, M., Y.C. Lee, and W.P. Tew, Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data. American Society of Clinical Oncology Educational Book, 2023(43).

34.

Tookman L, et al. Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Ther Adv Med Oncol. 2020;12:1758835920921980.PubMedPubMedCentralCrossRef

35.

Elliott L, et al. The clinical guide to oncology nutrition. 2nd ed. Chicago, Ill: American Dietetic Association; 2006.

36.

Morice PM, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8(2):e122–34.PubMedCrossRef

37.

DiSilvestro P, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41(3):609–17.PubMedCrossRef

38.

Noordermeer SM, van Attikum H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29(10):820–34.PubMedCrossRef

39.

Rottenberg S, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079–84.PubMedPubMedCentralCrossRefADS

40.

Vaidyanathan A, et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016;115(4):431–41.PubMedPubMedCentralCrossRef

41.

Murai J, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99.PubMedPubMedCentralCrossRef

42.

Pettitt SJ, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018;9(1):1849.PubMedPubMedCentralCrossRefADS

43.

Edwards SL, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451(7182):1111–5.PubMedCrossRefADS

44.

Fong PC, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512–9.PubMedCrossRef

45.

Swisher EM, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021;12(1):2487.PubMedPubMedCentralCrossRefADS

46.

Frenel JS, et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. 2022;33(10):1021–8.PubMedCrossRef

47.

Wang N, et al. PARP inhibitor resistance in breast and gynecological cancer: resistance mechanisms and combination therapy strategies. Front Pharmacol. 2022;13:967633.PubMedPubMedCentralCrossRef

48.

Ray Chaudhuri A, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535(7612):382–7.PubMedCrossRefADS

49.

Bouwman P, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17(6):688–95.PubMedPubMedCentralCrossRef

50.

Yazinski SA, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31(3):318–32.PubMedPubMedCentralCrossRef

51.

Yamaguchi H, et al. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene. 2018;37(2):208–17.PubMedCrossRef

52.

Yamamoto H, Hirasawa A. Homologous recombination deficiencies and hereditary tumors. Int J Mol Sci. 2021;23(1):348. https://doi.org/10.3390/ijms23010348.

53.

Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract. 2017;4:4.PubMedPubMedCentralCrossRef

54.

Gonzalez D, Stenzinger A. Homologous recombination repair deficiency (HRD): from biology to clinical exploitation. Genes Chromosomes Cancer. 2021;60(5):299–302.PubMedCrossRef

55.

Swisher EM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.PubMedCrossRef

56.

Tung NM, et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38(36):4274–82.PubMedCrossRef

57.

Mehta AK, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021;2(1):66–82.PubMedCrossRef

58.

Wielgos ME, et al. Trastuzumab-resistant HER2(+) breast cancer cells retain sensitivity to poly (ADP-Ribose) polymerase (PARP) inhibition. Mol Cancer Ther. 2018;17(5):921–30.PubMedPubMedCentralCrossRef

59.

Stringer-Reasor EM, et al. Trial in progress: a phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050). J Clin Oncol. 2021;39(15_suppl):TPS1098-TPS1098.CrossRef

60.

Nowsheen S, et al. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res. 2012;72(18):4796–806.PubMedPubMedCentralCrossRef

61.

Dieras V, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(10):1269–82.PubMedCrossRef

62.

Schmid P, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21.PubMedCrossRef

63.

Walsh RJ, Sundar R, Lim JSJ. Immune checkpoint inhibitor combinations-current and emerging strategies. Br J Cancer. 2023;128(8):1415–7.PubMedPubMedCentralCrossRef

64.

Konstantinopoulos PA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141–9.PubMedPubMedCentralCrossRef

65.

Lee JM, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women’s cancers: a dose-escalation, phase I study. J Clin Oncol. 2017;35(19):2193–202.PubMedPubMedCentralCrossRef

66.

Ding L, et al. PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972–2980 e5.PubMedPubMedCentralCrossRef

67.

Domchek SM, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–64.PubMedCrossRef

68.

Ray-Coquard I, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–28.PubMedCrossRef

Title: PARP Inhibitors in Breast Cancer: a Short Communication
Authors: Gordon R. Daly
Maen Monketh AlRawashdeh
Jason McGrath
Gavin P. Dowling
Luke Cox
Sindhuja Naidoo
Damir Vareslija
Arnold D. K Hill
Leonie Young
Publication date: 02-01-2024
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Ovarian Cancer
Ovarian Cancer
Published in: Current Oncology Reports / Issue 2/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01488-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2024

Prolymphocytic Leukaemia: an Update on Biology and Treatment

Germline Mutations and Ancestry in Prostate Cancer

Integrative Oncology Approaches to Reduce Recurrence of Disease and Improve Survival

Time-limited therapy in chronic lymphocytic leukemia

Elderly Rectal Cancer: An Updated Review

Sarcopenia and Neuroendocrine Neoplasms

Keynote webinar | Spotlight on antibody–drug conjugates in cancer